Forget the oral wig: This weight-loss drug might be an even bigger winner
In January, New Nordisk (NYSE: NVO ) Vigoi has broken new ground in the weight loss market by launching an oral version of its popular anti-obesity drug. It is the first oral GLP-1 approved for long-term weight management, and Novo Nordisk hopes it will help it regain market share in this area. While Oral Vigovi … Read more